Minnesota 2023-2024 Regular Session

Minnesota Senate Bill SF2266

Introduced
3/1/23  

Caption

Pharmacist dispensing of prescriptions using an audible container or braille container label for patients who are visually impaired or blind requirement

Impact

The enactment of SF2266 would amend Minnesota Statutes 2022, specifically section 151.212, by requiring pharmacists to inform patients about the availability of these accessible prescription drug container labels. This would foster an environment where patients with disabilities can manage their medications independently and with confidence. The bill outlines specific requirements for label content and format, ensuring that the information conveyed is thorough, accessible, and aligned with best practices established by the United States Access Board.

Summary

SF2266 is a legislative proposal aimed at enhancing accessibility to prescription medications for individuals who are blind or visually impaired. The bill mandates that pharmacies provide audible or braille labels upon request, ensuring that patients who identify as having a disability can receive prescription drugs labeled in a manner that accommodates their needs. The intention behind this legislation is to empower individuals with disabilities by giving them more autonomy in managing their medications safely and effectively.

Conclusion

Overall, SF2266 represents a significant step toward enhancing access to healthcare for visually impaired individuals in Minnesota. As discussions around the bill progress, it will be essential to closely examine both the benefits for patients and the implications for pharmacies operating under the new regulations to ensure a smooth and effective implementation of these important accessibility features.

Contention

While SF2266 aims to improve accessibility, it could face pushback regarding its implementation. Some concerns may arise around the additional pressures placed on pharmacies to adopt new labeling systems and ensure compliance with the bill's requirements. Stakeholders, including pharmacy representatives, might argue about the cost implications and practical challenges related to training staff and updating systems to fulfill these mandates. Proponents of the bill may counter that the long-term benefits of increased accessibility far outweigh the initial challenges and costs.

Companion Bills

MN HF2430

Similar To Pharmacists required to dispense prescription using an audible container label or braille container label for patients who are visually impaired or blind.

Previously Filed As

MN HF2430

Pharmacists required to dispense prescription using an audible container label or braille container label for patients who are visually impaired or blind.

MN HB374

Regards prescription drug readers for visually impaired patients

MN HB382

Regards prescription drug readers for visually impaired patients

MN HB2291

Opioids; containers; labeling; requirements; repeal

MN SB1254

Opioids; containers; labeling; requirements; repeal

MN HB456

State Board of Pharmacy - Accessible Prescription Labels, Bag Tags, and Medical Guides for Blind, Visually Impaired, and Print Disabled Individuals - Regulations

MN SB940

State Board of Pharmacy - Accessible Prescription Labels, Bag Tags, and Medical Guides for Blind, Visually Impaired, and Print Disabled Individuals - Regulations

MN AB1902

Prescription drug labels: accessibility.

MN HB516

Prescription drugs; labels provided for blind and disabled users.

MN HB06872

An Act Concerning The Labeling Of Prescription Drug Containers Containing Opiates.

Similar Bills

CA AB2789

Health care practitioners: prescriptions: electronic data transmission.

CA AB852

Health care practitioners: electronic prescriptions.

CA AB149

Controlled substances: prescriptions.

TX SB594

Relating to the regulation of prescriptions for controlled substances, including certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2246

Relating to certain procedures applicable to electronic prescriptions for Schedule II controlled substances.

TX HB2766

Relating to electronic and other controlled substance prescriptions under the Texas Controlled Substances Act; authorizing a fee.